<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2524">
  <stage>Registered</stage>
  <submitdate>6/10/2009</submitdate>
  <approvaldate>6/10/2009</approvaldate>
  <nctid>NCT00992576</nctid>
  <trial_identification>
    <studytitle>Optimisation of Hydromorphone - Naloxone Ratio for the Treatment of Pain</studytitle>
    <scientifictitle>A Confirmatory, Placebo-controlled, Randomised, Double-blind, Single-dummy, Parallel Group, Ratio-finding Study in Constipated Pain Patients to Establish an Optimal Hydromorphone - Naloxone Ratio With an Improved Bowel Function and a Comparable Analgesic Efficacy Compared to Hydromorphone Alone</scientifictitle>
    <utrn />
    <trialacronym>HMX3501</trialacronym>
    <secondaryid>2008-005312-18</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Constipation</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Active Hydromorphone PR + Active Naloxone PR
Treatment: drugs - Active Hydromorphone PR + Placebo Naloxone PR

Treatment: drugs: Active Hydromorphone PR + Active Naloxone PR
Optimal pain relief and improved bowel function in constipated pain patients

Treatment: drugs: Active Hydromorphone PR + Placebo Naloxone PR
Optimal pain relief and improved bowel function in constipated pain patients

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Bowel Function Measure Average pain scores</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Bowel Function Measures Rescue medication use</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Male or female subjects at least 18 years with a history of non-cancer or cancer pain
             that requires around-the-clock opioid therapy (8, 24 or 48 mg hydromorphone PR per day
             for the duration of the study).

          2. Subjects with constipation caused or aggravated by opioids

          3. Subjects must be willing to discontinue their current opioid analgesic routine, and .

          4. current laxative regimen</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Chronic or intermittent pain that results from Fibromyalgia or Rheumatoid Arthritis.

          2. Subjects presently taking, or who have taken, naloxone &lt;=30 days prior to the start of
             the Screening Period.

          3. Subjects suffering from diarrhoea.

          4. Abnormal liver or kidney function.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Hunter New England Area Health Service - Newcastle</hospital>
    <postcode>2300 - Newcastle</postcode>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Pribram</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>KÃ¸benhavn K.</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Kuopio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Amiens Cedex 1</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Jena</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Zeist</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Cluj-Napoca</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Aarau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Chesterfield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Mundipharma Research GmbH &amp; Co KG</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to establish an optimal hydromorphone - naloxone ratio with an
      improved bowel function for constipated pain patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00992576</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>